Checkpoint inhibition: protecting against or predisposing for second primary tumors? Reply to the Letter to the Editor 'Checkpoint inhibition: protecting against or predisposing for second primary tumors?' by K. P. M. Suijkerbuijk, A. M. May and M. J. M. van Eijs
- PMID: 33932506
- DOI: 10.1016/j.annonc.2021.04.017
Checkpoint inhibition: protecting against or predisposing for second primary tumors? Reply to the Letter to the Editor 'Checkpoint inhibition: protecting against or predisposing for second primary tumors?' by K. P. M. Suijkerbuijk, A. M. May and M. J. M. van Eijs
Conflict of interest statement
Disclosure DP, IR-C, J-YB report research support and honoraria from Roche, Bristol-Myers Squibb, Merck Sharp & Dohme, AstraZeneca, GlaxoSmithKline, and Novartis. All other authors have declared no conflicts of interest. Ethical approval The work was approved by the internal review board of the Centre Léon Bérard. Only patients not opposed to the re-analysis of their anonymized health data within internal academic studies were included according to the standard operating procedures of the Centre Léon Bérard and to the national and European Union (EU) legislation.
Comment on
-
Checkpoint inhibition: protecting against or predisposing for second primary tumors?Ann Oncol. 2021 Jul;32(7):935. doi: 10.1016/j.annonc.2021.03.202. Epub 2021 Mar 29. Ann Oncol. 2021. PMID: 33794292 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources